Yes, a balanced article that gives weight to each of the major...

Yes, a balanced article that gives weight to each of the major players.

With the listing of Harvest One too, it bring to mind how does one value MMJ? There is seemingly a dichotomy between two schools of thought:
Parity v Percentage

There is valid reasoning behind both, yet I feel a percentage based approach fails to take into account the bigger picture, and undervalues MMJ presently. As the 'investment company' and based on percentage ownership (circa 60%), the HVST SP needs to be $1 for MMJ to hold at 60c. If HVST remains at its current levels, then it severely undervalues MMJ at circa 29-30c. That said, it fails to take into consideration the therapeutics division of MMJ whereby this is where the current market potential lies. The article hammers this home in terms of commercialisation.

The Harvest One listing felt rushed to me, and all things considered, a listing backed by an upgraded sell license and definitive Australian Gelpell distribution, would've set the SP alight.